After Conquering Diabetes, BP Adams Shares Book, Diet That Helped Save His Life!

After Conquering Diabetes, BP Adams Shares Book, Diet That Helped Save His Life!
The best thing to happened to me in my life is that I became diabetic, because if I wasnt diabetic, I was going to die from one of the 15 American diseases, said BP Eric Adams.
Brooklyn Borough President Eric L. Adams works out on a machine he has added to his office as a part of a change in his lifestyle and diet.
Brooklyn Borough President Eric L. Adams is on a mission to improve the health of Brooklyn. That includes the boroughs economic health, social health, mental health, but most importantly, the physical health of its residents. And Adams is leading by example, starting with himself!
In April 2016, during a routine health checkup, Adams learned he had Type 2 diabetes a lab test showed that his average level of blood glucose was three times that of a normal patient, and the doctor was surprised he had not already lapsed into a coma.
He thought about his mother, who also suffered from high blood pressure and the onset of diabetes, and so he figured his condition was hereditary. Immediately, he began to research every diet plan available to figure out how he could lose the weight quickly.
Disease is not in your DNA; its in your dinner!
He went online, watched videos, read articles, manuals, medical studies. One of the most valuable books he came across during his search was How Not to Die , by Dr. Michael Greger, M.D. a book the borough president says pretty much saved his life.
In that book he learned that the cause of diabetes and most other illnesses was not genetic, nor was Continue reading

Rate this article

Total 1 ratings

Diabetes Risk and Moderate Drinking

Researchers also looked at what people were drinking.
Men and women who had seven or more glasses of wine per week had a 25-30 percent lower risk of diabetes, compared with people who had less than one drink per week, according to a press release .
This fits with an earlier meta-analysis of 13 studies that found that moderate wine drinkers had a 20 percent lower risk of diabetes, compared with abstainers or light drinkers.
The researchers suggest that natural phytochemical compounds found in red wine may have beneficial effects on blood sugar levels.
Men who drank between one and six beers each week had a 21 percent lower risk of diabetes, compared with men who drank less than one beer each week. Researchers found no link between beer drinking and diabetes risk in women.
In women, drinking seven or more drinks of liquor each week increased their risk of diabetes by 83 percent, compared with women who drank less than one each week. There was no link between mens liquor consumption and their diabetes risk.
A relatively small number of people in the study, though, reported heavy consumption of spirits.
Dr. William Cefalu, chief scientific, medical, and mission officer for the American Diabetes Association, cautioned that given the observational nature of the data, its difficult to draw firm conclusions about any real difference between men and women in the effect of spirit consumption.
Cefalu told Healthline that one of the strengths of the study was the large number of people surveyed.
But he said the study had certain limitations, including a small number of peopl Continue reading

Closed-Loop Insulin Pump Brightens Future of Diabetes Management

Closed-Loop Insulin Pump Brightens Future of Diabetes Management
This story is part ofMD Magazine's Year-End Recap series.
Click here for Part 1 , a look into the success of ketamine as a multifaceted therapy.
Click here for Part 2 , a look at the future of Alzheimer's Disease therapies.
For patients with type 1 diabetes (T1D), one of the biggest burdens of the condition is the need to manage it - more specifically, to manage their blood glucose levels .
With the September 2016 approval of the MiniMed670GInsulin Pump System by the US Food and Drug Administration (FDA), produced by Medtronic, the patients ability to manage their glucose became much easier.
Normally, patients with T1D need to monitor their continuous glucose monitoring sensor and use the information the sensor provides them to predict and adjust the dose of insulin they set their pump toadminister. While that open loop system is a major improvement from the previously used multiple daily injections, it still puts a burden on the patient, especially at night and for pediatric patients.
Medtronics device, however, is the first of its kind featuring a closed loop system that self-adjusts to the individual wearer. This allows for real-time alterations in insulin based on the needs at the time, and it is currently the only such device on the market that is able to control dosing automatically. Now, the system does the work for the patient.
Our previous approach with the old pump systems, with set basal rates of insulin infusion that change every couple hours at most, was very nave and inadequate, Kevin P Continue reading

Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Abstract
Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) has already been proven an efficient treatment option for type 2 diabetes. This combination can effectively improve glycated hemoglobin levels, cause weight loss and reduce the dosage of insulin. In addition, it can also reduce the risk of hypoglycemia. Several randomized controlled trials have confirmed that this treatment may be just as effective for type 1 diabetes mellitus (T1DM) patients. The objective of this meta-analysis was to assess the effects and efficacy of the treatment on glycemic changes, weight loss and insulin dosage in type 1 diabetes mellitus patients.
We searched Embase, PubMed and Cochrane for randomized controlled trials (no time restrictions) that investigated combined insulin and GLP-1 treatment. The main endpoints were measurements of glycated hemoglobin and changes in the weight and the dosage of insulin.
In total, 1093 were studies identified, and 7 studies were included in our meta-analysis. GLP-1 agonist and insulin combination therapy led to greater reductions in HbA1c levels [P = 0.03; mean difference −0.21; 95% confidence intervals (CI) (−0.40, 0.02)] and weight [P < 0.05; −3.53 (−4.86, 2.19)] compared to control treatments. The combination therapy did not significantly influence the daily weight-adjusted total insulin dose [P = 0.05; −0.11 (−0.23, 0)], but it did reduce the daily weight-adjusted bolus insulin dose [P = 0.001; −0.06 (−0.1, 0.02)].
Our meta-analysis supports the use of a combined therapeutic regimen of insulin an Continue reading

The use of animal models in diabetes research

The use of animal models in diabetes research
Diabetes Research Group, King's College London, London, UK
Aileen King, Diabetes Research Group, Guy's Campus, King's College London, London SE1 1UL, UK. E-mail: [email protected]
Received 2011 Aug 19; Revised 2012 Feb 10; Accepted 2012 Feb 13.
Copyright 2012 The Author. British Journal of Pharmacology 2012 The British Pharmacological Society
This article has been cited by other articles in PMC.
Diabetes is a disease characterized by a relative or absolute lack of insulin, leading to hyperglycaemia. There are two main types of diabetes: type 1 diabetes and type 2 diabetes. Type 1 diabetes is due to an autoimmune destruction of the insulin-producing pancreatic beta cells, and type 2 diabetes is caused by insulin resistance coupled by a failure of the beta cell to compensate. Animal models for type 1 diabetes range from animals with spontaneously developing autoimmune diabetes to chemical ablation of the pancreatic beta cells. Type 2 diabetes is modelled in both obese and non-obese animal models with varying degrees of insulin resistance and beta cell failure. This review outlines some of the models currently used in diabetes research. In addition, the use of transgenic and knock-out mouse models is discussed. Ideally, more than one animal model should be used to represent the diversity seen in human diabetic patients.
This paper is the latest in a series of publications on the use of animal models in pharmacology research. Readers might be interested in the previous papers.
Robinson V (2009). Less is more: reducin Continue reading